Sinatra Laura, Yang Jing, Schliehe-Diecks Julian, Dienstbier Niklas, Vogt Melina, Gebing Philip, Bachmann Luisa M, Sönnichsen Melf, Lenz Thomas, Stühler Kai, Schöler Andrea, Borkhardt Arndt, Bhatia Sanil, Hansen Finn K
Institute for Drug Discovery, Medical Faculty, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany.
Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.
J Med Chem. 2022 Dec 22;65(24):16860-16878. doi: 10.1021/acs.jmedchem.2c01659. Epub 2022 Dec 6.
In this work, we utilized the proteolysis targeting chimera (PROTAC) technology to achieve the chemical knock-down of histone deacetylase 6 (HDAC6). Two series of cereblon-recruiting PROTACs were synthesized via a solid-phase parallel synthesis approach, which allowed the rapid preparation of two HDAC6 degrader mini libraries. The PROTACs were either based on an unselective vorinostat-like HDAC ligand or derived from a selective HDAC6 inhibitor. Notably, both PROTAC series demonstrated selective degradation of HDAC6 in leukemia cell lines. The best degraders from each series (denoted and ) were capable of degrading HDAC6 via ternary complex formation and the ubiquitin-proteasome pathway, with DC values of 3.5 and 19.4 nM, respectively. PROTAC demonstrated promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines. These findings highlight the potential of this series of degraders as effective pharmacological tools for the targeted degradation of HDAC6.
在本研究中,我们利用蛋白酶靶向嵌合体(PROTAC)技术实现了组蛋白去乙酰化酶6(HDAC6)的化学敲低。通过固相平行合成方法合成了两个系列的cereblon招募PROTAC,这使得能够快速制备两个HDAC6降解剂微型文库。这些PROTAC要么基于非选择性的伏立诺他样HDAC配体,要么源自选择性HDAC6抑制剂。值得注意的是,两个PROTAC系列均在白血病细胞系中表现出对HDAC6的选择性降解。每个系列中最佳的降解剂(分别表示为 和 )能够通过三元复合物形成和泛素-蛋白酶体途径降解HDAC6,DC值分别为3.5和19.4 nM。PROTAC 通过在髓系白血病细胞系中诱导凋亡表现出有前景的抗增殖活性。这些发现突出了这一系列降解剂作为靶向降解HDAC6的有效药理学工具的潜力。